Godavari Drugs Q4 FY26 Results: Revenue, PAT, Net Profit and Key Highlights

Godavari Drugs Q4 FY26 results were declared on May 27, 2026. The company declared results for the quarter ended March 31, 2026. Revenue from operations was Rs 33.16 crore, +30.0% YoY from Rs 25.5 crore. Results are on a standalone basis. Godavari Drugs is a leading Bulk Drugs and API Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Godavari Drugs Q4 FY26 Financial Highlights

Metric	Q4 FY26	Q4 FY25	YoY Change
Revenue from Operations (Rs Cr)	33.16	25.5	+30.0%
Net Profit (PAT) (Rs Cr)	N/A	N/A	N/A
Reporting Basis	Standalone

Note: Q4 FY26 Revenue Rs 33.16 Cr (+30.04% YoY). Net profit details in BSE/NSE audited filing. Always verify from BSE/NSE audited filings before investment decisions.

Godavari Drugs Q4 FY26 Performance Analysis

The Godavari Drugs Q4 FY26 results reflect performance in the January to March 2026 quarter. Revenue from operations grew to Rs 33.16 crore, +30.0% YoY during the quarter. Godavari Drugs operates in the Bulk Drugs and API Pharmaceuticals sector and demonstrated resilience amid India’s GDP growth above 6.5% in FY26.

India’s macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth, government capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. The Bulk Drugs and API Pharmaceuticals sector benefited from these structural tailwinds during the January to March 2026 quarter.

Key Business Factors in Q4 FY26

Revenue and Volume Performance

Revenue from operations in Godavari Drugs Q4 FY26 grew to Rs 33.16 crore, +30.0% YoY. Strong demand drove the revenue performance. The Bulk Drugs and API Pharmaceuticals sector benefited from India’s domestic demand recovery and infrastructure push in FY26.

Profitability and Margin Trajectory

Net profit details for Godavari Drugs Q4 FY26 are available in the BSE/NSE audited filing declared May 27, 2026. Investors should refer to audited financials before making investment decisions.

Sector and Macro Backdrop

India’s macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI’s accommodative policy stance. These factors supported business investment and consumer spending. The Bulk Drugs and API Pharmaceuticals sector benefited from these structural tailwinds during the quarter ended March 31, 2026.

Dividend Details

No dividend was declared for Q4 FY26. The company channelled cash towards operational growth and balance sheet strength in Q4 FY26.

FY27 Outlook

Following the Godavari Drugs Q4 FY26 results, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and order book health. Stable Q4 FY26 execution supports a constructive FY27 outlook. India’s GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Godavari Drugs in FY27.

Godavari Drugs Stock Performance

Download the Univest iOS App or Univest Android App to track live price and daily stock recommendations.

Shares of Godavari Drugs are listed on NSE and BSE. Following the Q4 FY26 results on May 27, 2026, investors should monitor post-results price action, institutional activity, and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.

Key Risks

Input Cost and Margin Volatility

Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks for Godavari Drugs in FY27. Any cost escalation without corresponding pricing power could compress margins from Q4 FY26 levels.

Demand and Revenue Slowdown Risk

Any deceleration in India’s GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Godavari Drugs’s products and services in the Bulk Drugs and API Pharmaceuticals sector in FY27.

Regulatory and Competitive Risk

Changes in regulatory frameworks, competitive pricing pressure from domestic and global peers, and customer concentration risks are key watchpoints for Godavari Drugs investors. Sustained execution against strategic priorities remains critical.

Conclusion

Godavari Drugs Q4 FY26 results declared on May 27, 2026 showed revenue of Rs 33.16 crore, +30.0% YoY. Revenue +30.0% YoY demonstrates strong topline momentum. The results reinforce the company’s execution capability heading into FY27. Investors should monitor management guidance, sector trends, and macroeconomic developments before making investment decisions.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE/NSE audited filings.

Frequently Asked Questions on Godavari Drugs Q4 FY26 Results

What is Godavari Drugs Q4 FY26 net profit?

Ans. Godavari Drugs Q4 FY26 net profit is available in the BSE/NSE audited filing declared May 27, 2026. Results declared May 27, 2026 on standalone basis.

What is Godavari Drugs Q4 FY26 revenue?

Ans. Godavari Drugs Q4 FY26 revenue was Rs 33.16 crore, +30.0% YoY. Results declared May 27, 2026.

When were Godavari Drugs Q4 FY26 results declared?

Ans. Godavari Drugs Q4 FY26 results were declared on May 27, 2026 at the board meeting approving audited financial statements for the quarter ended March 31, 2026.

What dividend did Godavari Drugs declare for FY26?

Ans. No dividend was declared for Q4 FY26. Verify from BSE/NSE filings for record date and payout schedule.

What is the FY27 outlook for Godavari Drugs?

Ans. Following Godavari Drugs Q4 FY26 results, management guidance on revenue growth, margin improvement, and capital allocation shapes FY27 expectations. Consult a SEBI-registered advisor before investing.

Is Godavari Drugs a good buy after Q4 FY26 results?

Ans. Investment in Godavari Drugs requires assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This article is for educational purposes only. Consult a SEBI-registered financial advisor.

What sector does Godavari Drugs operate in?

Ans. Godavari Drugs operates in the Bulk Drugs and API Pharmaceuticals sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 27, 2026.